A Phase I, Randomized Open-label, 2-period, Parallel Arm Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of "Filgrastim Hospira" (US) Or US-approved Neupogen(Registered) Reference Product In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Filgrastim (Primary)
- Indications Febrile neutropenia; Neutropenia
- Focus Pharmacodynamics
- Sponsors Pfizer
- 20 Feb 2017 Status changed from recruiting to completed.
- 29 Nov 2016 Status changed from not yet recruiting to recruiting.
- 07 Oct 2016 New trial record